DENTIS, a dental implant and medical equipment corporation, announced on the 6th that it has signed a strategic memorandum of understanding with the U.S. surgical equipment company "INFINIUM" and is embarking on a full-scale entry into the U.S. market. Established in 1991, INFINIUM is a U.S. surgical equipment solution corporation with global partners in 87 countries and has been supplying DENTIS's surgical table "LUVIS" to the U.S. market since 2016. The two companies agreed to cooperate in supplying surgical room solutions that combine surgical tables and operations in the U.S. market and to enhance brand recognition.
CLASSYS announced on the 6th that the use of its beauty medical device Shrink Universe has expanded. Recently, CLASSYS received additional approval from the Ministry of Food and Drug Safety for the 2mm cartridge of the Shrink Universe model, allowing for use not only in eyebrow lifting but also in "improving eye wrinkles, mouth wrinkles, and neck wrinkles." The Shrink series devices improve skin elasticity and wrinkles through high-intensity focused ultrasound (HIFU) energy and hold a 55% market share in the domestic HIFU market, making it the leading product.
GC Pharma announced on the 6th that the results of a large-scale big data analysis study on Fenofibrate, a treatment for hypertriglyceridemia, have recently been published in the renowned endocrine journal "Diabetes, Obesity and Metabolism." Professor Park Cheol-young of the Endocrinology Department at Gangbuk Samsung Hospital, who conducted the study, analyzed data from over 1.46 million patients who took statin medications for hypertriglyceridemia from 2010 to 2017, comparing those who were prescribed Fenofibrate with those who were not, each group containing 413,715 patients. The analysis indicated that the group taking Fenofibrate experienced a 24% reduction in the occurrence of end-stage renal disease compared to the control group. The renal protective effect of Fenofibrate was particularly pronounced in patients with hypertension, proteinuria, and moderate kidney disease.
Hanall Biopharma, Korea AstraZeneca, and Amgen Korea each announced on the 6th that they have received certification as "innovative pharmaceutical corporations" from the Ministry of Health and Welfare. The certification system for innovative pharmaceutical corporations, established to create an innovation ecosystem focused on new drug development, has been awarding certifications since 2012 to corporations with outstanding research and development performance. Certified corporations can receive various support, including advantages in R&D support programs, pricing preferences, and tax benefits.
The Jaseng Medical Foundation announced on the 6th that it has transferred the Gwanghwamun Jaseng Korean Medicine Hospital in Jung-gu, Seoul, to Dongjak-gu, where it has opened the "Boramae Jaseng Korean Medicine Hospital." The Boramae Jaseng Korean Medicine Hospital has a total of 50 intensive care beds, comprising six 4-person rooms, four 3-person rooms, and seven 2-person rooms, and will continue systematic Hyupjin consultations with 12 Korean medicine doctors across eight Korean medicine specialties and two Western medicine specialties (radiology and general internal medicine) staffed by two Western medicine doctors. Utilizing advanced imaging equipment like magnetic resonance imaging (MRI) and X-Ray, the hospital will offer precise examinations and results confirmation and treatment on the same day patients visit.